ClinicalTrials.gg
TerminatedNCT03556202Updated Mar 21, 2023Results posted

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

A Phase 3 interventional study of Mirikizumab in Psoriasis, sponsored by Eli Lilly and Company. Terminated at 229 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-21.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated due to a strategic business decision made by the Sponsor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,936
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.

Enrollment
Largest of 36
1,936 · median 181
Started
2018
with 5 others
Phase 3
15 of 36
none open now
Registered
24th of 36
by date

Among the 36 studies in Psoriasis by Eli Lilly and Company, this one has the largest enrollment, is one of 6 that started in 2018, is one of 15 in phase 3, and was the 24th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Psoriasis by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • IL-23
  • Interleukin-23
  • Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have completed the last visit of an eligible study period of originating study.
  • Participant must be willing to follow the measures during and after study treatment if woman of .

Exclusion criteria

Exclusion Criteria:

  • Participant must not have an unstable or uncontrolled illness, including but not limited to a cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disease or abnormal lab results, that the study investigator thinks makes it unsafe or inappropriate for the participant to participate in this study.
  • Participant must not have stopped taking mirikizumab during a previous study or if the study investigator thinks restarting mirikizumab would create an unacceptable risk to the participant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,936 participants (actual)

Study arms

  • Experimental
    125 Milligram (mg) Mirikizumab Q8W

    Participants received 125 mg mirikizumab administered subcutaneously (SC) every eight weeks (Q8W).

    Drug: Mirikizumab

  • Experimental
    250 mg Mirikizumab Q8W Excluding Secukinumab

    Participants received 250 mg mirikizumab administered SC Q8W excluding participants who received secukinumab of their originating study (AMAJ)

    Drug: Mirikizumab

  • Experimental
    Secukinumab/250 mg Mirikizumab Q8W

    Participants from previous originating study \[who received secukinumab (AMAJ)\] received 250 mg mirikizumab administered SC Q8W.

    Drug: Mirikizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Static Physician's Global Assessment Among Those Who Entered the Study With a sPGA of 0,1

    The sPGA is the physician's determination of the participant's psoriasis (PsO) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 104 were considered non-responders for non-responder Imputation (NRI) analysis.

    Time frame: Week 104

  2. Percentage of Participants Who Maintained a ≥90% Improvements in Psoriasis Area and Severity Index (PASI) 90 Among Those Who Entered the Study With a PASI 90

    PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).

    Time frame: Week 104

Secondary outcomes

  1. Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)

    PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).

    Time frame: Week 104

  2. Percentage of Participants With a Psoriasis Symptoms Scale (PSS) Symptom Score of 0 (Free of Itch, Pain, Stinging, and Burning) in Those With a PSS Symptoms Score ≥1 at Baseline

    PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. In addition, a symptoms score ranging from 0 (no symptoms) to 40 (worst imaginable symptoms), and a sign score of 0 (no signs) to 30 (worst imaginable signs) will be reported.

    Time frame: Week 104

  3. Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Total Score of (0,1) With at Least a 5-Point Improvement (Reduction) From Baseline in Participants With a Baseline DLQI Total Score ≥5

    The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Totals range from 0 to 30 (less to more impairment). A DLQI total score of 0 to 1 is considered as having no effect on a patient's health-related quality of life (HRQoL), and a 5-point change from baseline is considered as the minimal clinically important difference (MCID) threshold.

    Time frame: Week 104

  4. Change in Palmoplantar Psoriasis Severity Index (PPASI) Total Score in Participants With Palmoplantar Involvement at Baseline

    The PPASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline.

    Time frame: Baseline, Week 104

  5. Change in Psoriasis Scalp Severity Index (PSSI) Total Score in Participants With Scalp Involvement at Baseline

    The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity).

    Time frame: Baseline, Week 104

  6. Change in Nail Psoriasis Severity Index (NAPSI) Total Score in Participants With Fingernail Involvement at Baseline

    The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix PsO by area of involvement. The fingernail is divided into quadrants. Each fingernail is given a score for fingernail bed PsO 0 (none) to 4 (PsO in 4 quadrants of the fingernail) and fingernail matrix PsO 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix PsO in each quadrant. The sum of all fingernails equals the total NAPSI score range is from 0 (no effect) to 80 (more severe psoriasis).

    Time frame: Baseline, Week 104

07

Results

Posted Mar 21, 2023
Limitations and caveats
This study was terminated before completion of the long-term extension trial, due to strategic business decision made by the company.

Participant flow

Extension Treatment Period
Participant flow — Extension Treatment Period
Milestone125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8W
Started5271020389
Received at least one dose of study drug5271020389
From amaf351320
From amak833900
From amaj409498389
Completed000
Not completed5271020389
Withdrew: Adverse event18149
Withdrew: Death260
Withdrew: Lack of efficacy51218
Withdrew: Lost to follow-up9202
Withdrew: Pregnancy243
Withdrew: Study terminated by sponsor469907331
Withdrew: Withdrawal by subject224722
Withdrew: Due to exclusion criteria of amaj study001
Withdrew: Physician decision082
Withdrew: Protocol violation011
Withdrew: Sponsor decision010
Follow-Up Period (12 Weeks)
Participant flow — Follow-Up Period (12 Weeks)
Milestone125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8W
Started453861333
Completed000
Not completed453861333
Withdrew: Adverse event11118
Withdrew: Death100
Withdrew: Lack of efficacy4913
Withdrew: Lost to follow-up4143
Withdrew: Pregnancy141
Withdrew: Study terminated by sponsor396750273
Withdrew: Withdrawal by subject366531
Withdrew: Physician decision031
Withdrew: Site terminated by sponsor010
Withdrew: Study discontinued by sponsor021
Withdrew: Second follow-up visit: patient refused010
Withdrew: Study terminated & subject missed follow-up visit010
Withdrew: To meet exclusion criteria of the amaj study001
Withdrew: Second follow-up not done, unable to reach patient001

Outcome measures

PrimaryPercentage of Participants With a Static Physician's Global Assessment Among Those Who Entered the Study With a sPGA of 0,1

The sPGA is the physician's determination of the participant's psoriasis (PsO) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 104 were considered non-responders for non-responder Imputation (NRI) analysis.

Time frame:
Week 104
Reported as:
Number · percentage of participants
Percentage of Participants With a Static Physician's Global Assessment Among Those Who Entered the Study With a sPGA of 0,1
percentage of participants125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8W
Percentage of Participants With a Static Physician's Global Assessment Among Those Who Entered the Study With a sPGA of 0,146.7 (42.2 to 51.2)55.7 (52.3 to 59.1)38.9 (33.3 to 44.4)
PrimaryPercentage of Participants Who Maintained a ≥90% Improvements in Psoriasis Area and Severity Index (PASI) 90 Among Those Who Entered the Study With a PASI 90

PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).

Time frame:
Week 104
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained a ≥90% Improvements in Psoriasis Area and Severity Index (PASI) 90 Among Those Who Entered the Study With a PASI 90
percentage of participants125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8W
Percentage of Participants Who Maintained a ≥90% Improvements in Psoriasis Area and Severity Index (PASI) 90 Among Those Who Entered the Study With a PASI 9049.3 (44.8 to 53.9)56.8 (53.4 to 60.2)39.4 (33.9 to 44.9)
SecondaryPercentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)

PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).

Time frame:
Week 104
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)
percentage of participants125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8W
Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)30.4 (26.4 to 34.3)36.4 (33.4 to 39.3)22.6 (18.5 to 26.8)
SecondaryPercentage of Participants With a Psoriasis Symptoms Scale (PSS) Symptom Score of 0 (Free of Itch, Pain, Stinging, and Burning) in Those With a PSS Symptoms Score ≥1 at Baseline

PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. In addition, a symptoms score ranging from 0 (no symptoms) to 40 (worst imaginable symptoms), and a sign score of 0 (no signs) to 30 (worst imaginable signs) will be reported.

Time frame:
Week 104
Reported as:
Number · percentage of participants
Percentage of Participants With a Psoriasis Symptoms Scale (PSS) Symptom Score of 0 (Free of Itch, Pain, Stinging, and Burning) in Those With a PSS Symptoms Score ≥1 at Baseline
percentage of participants125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8W
Percentage of Participants With a Psoriasis Symptoms Scale (PSS) Symptom Score of 0 (Free of Itch, Pain, Stinging, and Burning) in Those With a PSS Symptoms Score ≥1 at Baseline31.1 (27.1 to 35.1)33.6 (30.7 to 36.5)23.4 (19.1 to 27.7)
SecondaryPercentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Total Score of (0,1) With at Least a 5-Point Improvement (Reduction) From Baseline in Participants With a Baseline DLQI Total Score ≥5

The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Totals range from 0 to 30 (less to more impairment). A DLQI total score of 0 to 1 is considered as having no effect on a patient's health-related quality of life (HRQoL), and a 5-point change from baseline is considered as the minimal clinically important difference (MCID) threshold.

Time frame:
Week 104
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Total Score of (0,1) With at Least a 5-Point Improvement (Reduction) From Baseline in Participants With a Baseline DLQI Total Score ≥5
percentage of participants125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8W
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Total Score of (0,1) With at Least a 5-Point Improvement (Reduction) From Baseline in Participants With a Baseline DLQI Total Score ≥541.5 (37.1 to 45.9)47.3 (44.1 to 50.5)34.5 (29.5 to 39.5)
SecondaryChange in Palmoplantar Psoriasis Severity Index (PPASI) Total Score in Participants With Palmoplantar Involvement at Baseline

The PPASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline.

Time frame:
Baseline, Week 104
Reported as:
Mean · score on a scale
Change in Palmoplantar Psoriasis Severity Index (PPASI) Total Score in Participants With Palmoplantar Involvement at Baseline
score on a scale125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8W
Change in Palmoplantar Psoriasis Severity Index (PPASI) Total Score in Participants With Palmoplantar Involvement at Baseline-6.55 ± 7.058-6.80 ± 8.391-7.38 ± 6.632
SecondaryChange in Psoriasis Scalp Severity Index (PSSI) Total Score in Participants With Scalp Involvement at Baseline

The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity).

Time frame:
Baseline, Week 104
Reported as:
Mean · score on a scale
Change in Psoriasis Scalp Severity Index (PSSI) Total Score in Participants With Scalp Involvement at Baseline
score on a scale125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8W
Change in Psoriasis Scalp Severity Index (PSSI) Total Score in Participants With Scalp Involvement at Baseline-20.9 ± 15.79-19.5 ± 13.48-19.6 ± 13.44
SecondaryChange in Nail Psoriasis Severity Index (NAPSI) Total Score in Participants With Fingernail Involvement at Baseline

The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix PsO by area of involvement. The fingernail is divided into quadrants. Each fingernail is given a score for fingernail bed PsO 0 (none) to 4 (PsO in 4 quadrants of the fingernail) and fingernail matrix PsO 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix PsO in each quadrant. The sum of all fingernails equals the total NAPSI score range is from 0 (no effect) to 80 (more severe psoriasis).

Time frame:
Baseline, Week 104
Reported as:
Mean · score on a scale
Change in Nail Psoriasis Severity Index (NAPSI) Total Score in Participants With Fingernail Involvement at Baseline
score on a scale125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8W
Change in Nail Psoriasis Severity Index (NAPSI) Total Score in Participants With Fingernail Involvement at Baseline-19.4 ± 17.75-21.0 ± 17.69-22.2 ± 18.75

Adverse events

Collected over Treatment Period: Baseline Up To 160 Weeks, Follow-up Period: 0-12 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
125 Milligram (mg) Mirikizumab Q8W2/527 (0.4%)55/527 (10.4%)388/527 (73.6%)
250 mg Mirikizumab Q8W Excluding Secukinumab6/1,020 (0.6%)88/1,020 (8.6%)756/1,020 (74.1%)
Secukinumab/250 mg Mirikizumab Q8W0/389 (0%)35/389 (9%)288/389 (74%)
125 Milligram (mg) Mirikizumab Q8W Follow-up Period1/453 (0.2%)7/453 (1.5%)70/453 (15.5%)
250 mg Mirikizumab Q8W Excluding Secukinumab Follow-up Period0/861 (0%)6/861 (0.7%)120/861 (13.9%)
Secukinumab/250 mg Mirikizumab Q8W Follow-up Period0/333 (0%)0/333 (0%)47/333 (14.1%)
Most frequent serious events
Showing 10 of 174
Most frequent serious events
Event125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8W125 Milligram (mg) Mirikizumab Q8W Follow-up Period250 mg Mirikizumab Q8W Excluding Secukinumab Follow-up PeriodSecukinumab/250 mg Mirikizumab Q8W Follow-up Period
Covid-19 pneumoniaInfections and infestations5/5278/10202/3890/4530/8610/333
Neovaginal complicationInjury, poisoning and procedural complications0/1590/3091/1100/1300/2590/89
EndometriosisReproductive system and breast disorders0/1590/3091/1100/4530/8610/333
Haemorrhagic ovarian cystReproductive system and breast disorders0/1590/3091/1100/1300/2590/89
Uterine polypReproductive system and breast disorders0/1590/3091/1100/1300/2590/89
Acute myocardial infarctionCardiac disorders2/5272/10203/3890/4530/8610/333
CellulitisInfections and infestations0/5271/10202/3890/4530/8610/333
Atrial fibrillationCardiac disorders0/5274/10201/3890/4530/8610/333
Pancreatitis acuteGastrointestinal disorders2/5271/10200/3890/4530/8610/333
PneumoniaInfections and infestations2/5272/10201/3890/4530/8610/333
Most frequent other events
Showing 10 of 945
Most frequent other events
Event125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8W125 Milligram (mg) Mirikizumab Q8W Follow-up Period250 mg Mirikizumab Q8W Excluding Secukinumab Follow-up PeriodSecukinumab/250 mg Mirikizumab Q8W Follow-up Period
NasopharyngitisInfections and infestations55/527157/102043/3895/45311/8615/333
ArthralgiaMusculoskeletal and connective tissue disorders30/52787/102019/3890/4531/8612/333
Upper respiratory tract infectionInfections and infestations22/52754/102029/3895/4535/8614/333
Covid-19Infections and infestations33/52766/102026/38916/45311/8616/333
HeadacheNervous system disorders18/52755/102021/3892/4537/8612/333
Back painMusculoskeletal and connective tissue disorders25/52748/102020/3890/4534/8610/333
HypertensionVascular disorders22/52752/102014/3890/4533/8610/333
Injection site reactionGeneral disorders6/52719/102019/3891/4531/8610/333
CoughRespiratory, thoracic and mediastinal disorders16/52728/10208/3891/4532/8610/333
Urinary tract infectionInfections and infestations11/52730/10209/3890/4535/8611/333

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8WTotal
Mean47.90 ± 13.8147.00 ± 12.8746.50 ± 14.4147.10 ± 13.45
Sex: Female, Male
Sex: Female, Male(Participants)125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8WTotal
Female159309110578
Male3687112791358
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8WTotal
Hispanic or Latino296320112
Not Hispanic or Latino7915053282
Unknown or Not Reported4198073161542
Race (NIH/OMB)
Race (NIH/OMB)(Participants)125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8WTotal
American Indian or Alaska Native1548265
Asian8921763369
Native Hawaiian or Other Pacific Islander1113
Black or African American518629
White4157343151464
More than one race2226
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)125 Milligram (mg) Mirikizumab Q8W250 mg Mirikizumab Q8W Excluding SecukinumabSecukinumab/250 mg Mirikizumab Q8WTotal
Argentina32302385
Australia16211956
Canada26442494
Czechia25352888
France20151853
Germany6513642243
Hungary23272070
Israel12151542
Italy75517
Japan398637162
Mexico1556071
Poland7515747279
Russia343046
South Korea246813105
Spain24222470
Taiwan944053
United Kingdom2215
United States11021473397
08

Study locations

229 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Zenith Research, Inc.
    Beverly Hills, California 90212, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Keck School of Medicine University of Southern California
    Los Angeles, California 90033, United States
  • Dermatology Clinical Trials
    Newport Beach, California 92660-7831, United States
  • San Luis Dermatology & Laser Clinic
    San Luis Obispo, California 93405, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Univ of Connecticut
    Farmington, Connecticut 06030-2840, United States
  • Florida Academic Centers Research and Education, LLC
    Coral Gables, Florida 33134, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • ForCare Clinical Research
    Tampa, Florida 33613-1244, United States
  • Dermatologic Surgery Specialists, PC
    Macon, Georgia 31217, United States
  • Meridian Clinical Research
    Savannah, Georgia 31406, United States
  • Advanced Clinical Research LLC
    Meridian, Idaho 83642, United States
  • University Dermatology
    Darien, Illinois 60561, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • The South Bend Clinic Center for Research
    South Bend, Indiana 46617, United States
  • Forefront Research
    Louisville, Kentucky 40241, United States
  • DelRicht Research
    Baton Rouge, Louisiana 70809, United States
  • Dermatology and Skin Cancer Specialists
    Rockville, Maryland 20850, United States
  • Lawrence J Green, M.D, LLC
    Rockville, Maryland 20850, United States
  • ORA, Inc
    Andover, Massachusetts 01810, United States
  • Central Dermatology PC
    Saint Louis, Missouri 63117, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • Mount Sinai School of Medicine Dermatology Clinical Trials
    New York, New York 10029, United States
  • PMG Research of Cary, LLC
    Cary, North Carolina 27518, United States
  • University of North Carolina Dermatology and Skin Cancer Cen
    Chapel Hill, North Carolina 27516, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28411, United States
  • Bexley Dermatology Research
    Bexley, Ohio 43209, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Wright State Univ School of Medicine
    Fairborn, Ohio 45324, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • The Pennsylvania Centre for Dermatology, LLC
    Exton, Pennsylvania 19341, United States
  • Clinical Partners, LLC
    Johnston, Rhode Island 02919, United States
  • Modern Research Associates
    Dallas, Texas 75231, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • University of Utah
    Murray, Utah 84107, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23502, United States
  • Dermatology Associates
    Seattle, Washington 98101, United States
  • MultiCare Good Samaritan Hospital
    Tacoma, Washington 98405, United States
  • Dermatology
    Caba, Buenos Aires C1060ABN, Argentina
  • Instituto de Neumonología Y Dermatología
    Capital Federal, Buenos Aires 1425, Argentina
  • Psoriahue
    Ciudad Autonoma de Buenos Aire, Buenos Aires C1425DKG, Argentina
  • Buenos Aires Skin
    Buenos Aires, Ciudad Autónoma De Buenos Aire 1055, Argentina
  • Clinica Adventista Belgrano
    Caba, Ciudad Autónoma De Buenos Aire C1430EGF, Argentina
  • Centro de Investigaciones Metabólicas (CINME)
    Buenos Aires, C1027AAP, Argentina
  • Halitus Instituto Médico
    Ciudad Autonoma de Buenos Aire, C1122AAF, Argentina
  • Parra Dermatología
    Mendoza, 5500, Argentina
  • Woden Dermatology
    Phillip, Australian Capital Territory 2606, Australia
  • Veracity Clinical Research Pty Ltd
    Woolloongabba, Queensland 4102, Australia
  • Clinical Trials SA Pty Ltd
    Adelaide, South Australia 5073, Australia
  • Skin Health Institute Inc.
    Carlton, Victoria 3053, Australia
  • Fremantle Dermatology
    Perth, Western Australia 6160, Australia
  • Kirk Barber Research
    Calgary, Alberta T2G 1B1, Canada
  • Alberta DermaSurgery Centre
    Edmonton, Alberta T6G 1C3, Canada
  • Dr. Chih-ho Hong Medical Inc.
    Surrey, British Columbia V3R 6A7, Canada
  • Eastern Canada Cutaneous Research Assoicates Ltd
    Halifax, Nova Scotia B3H1Z2, Canada
  • Guenther Research Inc.
    London, Ontario N6A 3H7, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P1X2, Canada
  • SKiN Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Innovaderm Research Inc
    Montreal, Quebec H2X 2V1, Canada
  • Fakultni nemocnice Kralovske Vinohrady
    Praha 10, Hl. M. Praha 100 34, Czechia
  • Fakultni Nemocnice U svate Anny
    Brno, Jihomoravský Kraj 656 91, Czechia
  • Nemocnice AGEL Novy Jicin a.s.
    Novy Jicin, Moravskoslezsky Kraj 741 01, Czechia
  • Clintrial s.r.o.
    Praha, Praha 10 100 00, Czechia
  • Kožní ambulance Kutná Hora, s.r.o.
    Kutna Hora, Středočeský Kraj 28401, Czechia
  • Etická komise Krajské zdravotní, a.s. - Masarykovy nemocnice v Ústí nad Labem, o.z.
    Usti nad Labem, Ustecký Kraj 40113, Czechia
  • CHU Dupuytren 2
    Limoges, Cedex 87042, France
  • CHU de Bordeaux Hop St ANDRE
    Bordeaux, Gironde 33075, France
  • CH du Mans - Pavillon Claude Monet
    Le Mans Cedex 1, 72037, France
  • Cabinet Médical
    Martigues, 13500, France
  • Hopital Saint Eloi
    Montpellier, 34295, France
  • CHU de Nice Hopital de L'Archet
    Nice cedex 3, 06202, France
  • CHU Charles Nicolle in Rouen
    Rouen cedex, 76036, France
  • Hopital Larrey
    Toulouse cedex 9, 31059, France
  • Universitätsklinikum Heidelberg
    Heidelberg, Baden-Württemberg 69120, Germany
  • Hautarztpraxis Dr. Leitz
    Stuttgart, Baden-Württemberg 70178, Germany
  • Universitätsklinikum Tübingen
    Tübingen, Baden-Württemberg 72076, Germany
  • Dermatologische Gemeinschaftspraxis Mahlow
    Mahlow, Brandenburg 15831, Germany
  • Rosenpark Research GmbH
    Darmstadt, Hessen 64283, Germany
  • Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
    Frankfurt am Main, Hessen 60590, Germany
  • Fachklinik Bad Bentheim
    Bad Bentheim, Niedersachsen 48455, Germany
  • Dermatologisches Zentrum Osnabrück Nord
    Bramsche, Niedersachsen 49565, Germany
  • Elbe Klinikum Buxtehude
    Buxtehude, Niedersachsen 21614, Germany
  • Universitätsklinikum Münster
    Münster, Nordrhein-Westfalen 48149, Germany
  • Hautarztpraxis Dr. Gerlach
    Dresden, Sachsen 01097, Germany
  • Universitätsklinikum Schleswig-Holstein
    Kiel, Schleswig-Holstein 24105, Germany
  • Universitätsklinikum Schleswig-Holstein
    Lübeck, Schleswig-Holstein 23538, Germany
  • Charité Campus Virchow-Klinikum
    Berlin, 10117, Germany
  • Klin. Forschung Berlin-Mitte GmbH
    Berlin, 10117, Germany
  • Rothhaar Studien
    Berlin, 10783, Germany
  • ISA GmbH
    Berlin, 10789, Germany

Showing the first 100 of 229 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Feb 2022, 41 months.

Results were first posted in Mar 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2018
First posted
Jun 14, 2018
StartActual
Sep 3, 2018
Primary completionActual
Feb 7, 2022
CompletionActual
Feb 7, 2022
Results first posted
Mar 21, 2023
Last update
Mar 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03556202
Responsible party
Sponsor
First posted
Jun 14, 2018
Start date
Sep 3, 2018
Primary completion
Feb 7, 2022
Completion
Feb 7, 2022
Results posted
Mar 21, 2023
Last update
Mar 21, 2023

Study contacts

1-877-CTLILLY (1-877-285-4559) or Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion